Literature DB >> 30615138

PET imaging in patients with brain metastasis-report of the RANO/PET group.

Norbert Galldiks1,2,3, Karl-Josef Langen2,4, Nathalie L Albert5, Marc Chamberlain6, Riccardo Soffietti7, Michelle M Kim8, Ian Law9, Emilie Le Rhun10, Susan Chang11, Julian Schwarting12,13, Stephanie E Combs14, Matthias Preusser15, Peter Forsyth16, Whitney Pope17, Michael Weller18, Jörg C Tonn12,13.   

Abstract

Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  FDG PET; FET; amino acid PET; brain metastases; pseudoprogression

Year:  2019        PMID: 30615138      PMCID: PMC6502495          DOI: 10.1093/neuonc/noz003

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  110 in total

Review 1.  The role of surgery for brain metastases from solid tumors.

Authors:  Niklas Thon; Friedrich-Wilhelm Kreth; Joerg-Christian Tonn
Journal:  Handb Clin Neurol       Date:  2018

2.  Correction to: PET imaging of EGFR expression using an 18F-labeled RNA aptamer.

Authors:  Siyuan Cheng; Orit Jacobson; Guizhi Zhu; Zhen Chen; Steve H Liang; Rui Tian; Zhen Yang; Gang Niu; Xiaohua Zhu; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-11       Impact factor: 9.236

3.  Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation?

Authors:  Nilendu C Purandare; Ameya Puranik; Sneha Shah; Archi Agrawal; Tejpal Gupta; Aliasgar Moiyadi; Prakash Shetty; Epari Shridhar; Rakesh Jalali; Venkatesh Rangarajan
Journal:  Nucl Med Commun       Date:  2017-12       Impact factor: 1.690

4.  68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?

Authors:  Michael Sommerauer; Jan-Karl Burkhardt; Karl Frontzek; Elisabeth Rushing; Alfred Buck; Niklaus Krayenbuehl; Michael Weller; Niklaus Schaefer; Felix P Kuhn
Journal:  Neuro Oncol       Date:  2016-02-09       Impact factor: 12.300

5.  Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-methionine?

Authors:  Gérard Moulin-Romsée; Eduard D'Hondt; Tjibbe de Groot; Jan Goffin; Raf Sciot; Luc Mortelmans; Johan Menten; Guy Bormans; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

6.  (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.

Authors:  Karlo J Lizarraga; Martin Allen-Auerbach; Johannes Czernin; Antonio A F DeSalles; William H Yong; Michael E Phelps; Wei Chen
Journal:  J Nucl Med       Date:  2013-10-28       Impact factor: 10.057

Review 7.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Authors:  Hideho Okada; Michael Weller; Raymond Huang; Gaetano Finocchiaro; Mark R Gilbert; Wolfgang Wick; Benjamin M Ellingson; Naoya Hashimoto; Ian F Pollack; Alba A Brandes; Enrico Franceschi; Christel Herold-Mende; Lakshmi Nayak; Ashok Panigrahy; Whitney B Pope; Robert Prins; John H Sampson; Patrick Y Wen; David A Reardon
Journal:  Lancet Oncol       Date:  2015-11       Impact factor: 41.316

8.  The role of LAT1 in (18)F-DOPA uptake in malignant gliomas.

Authors:  Ryan S Youland; Gaspar J Kitange; Timothy E Peterson; Deanna H Pafundi; Judi A Ramiscal; Jenny L Pokorny; Caterina Giannini; Nadia N Laack; Ian F Parney; Val J Lowe; Debra H Brinkmann; Jann N Sarkaria
Journal:  J Neurooncol       Date:  2012-10-20       Impact factor: 4.130

9.  Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis.

Authors:  Giuseppe Minniti; Enrico Clarke; Gaetano Lanzetta; Mattia Falchetto Osti; Guido Trasimeni; Alessandro Bozzao; Andrea Romano; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2011-05-15       Impact factor: 3.481

10.  Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment.

Authors:  Ryogo Minamimoto; Toshiyuki Saginoya; Chisato Kondo; Noriaki Tomura; Kimiteru Ito; Yuka Matsuo; Shigeo Matsunaga; Takashi Shuto; Atsuya Akabane; Yoko Miyata; Shuji Sakai; Kazuo Kubota
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

View more
  45 in total

1.  Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.

Authors:  Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

2.  Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.

Authors:  Norbert Galldiks; Marcus Unterrainer; Natalie Judov; Gabriele Stoffels; Marion Rapp; Philipp Lohmann; Franziska Vettermann; Veronika Dunkl; Bogdana Suchorska; Jörg C Tonn; Friedrich-Wilhem Kreth; Gereon R Fink; Peter Bartenstein; Karl-Josef Langen; Nathalie L Albert
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

3.  Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.

Authors:  Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

4.  A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging.

Authors:  Aki Morikawa; Milan Grkovski; Sujata Patil; Komal L Jhaveri; Kendrick Tang; John L Humm; Andrei Holodny; Kathryn Beal; Heiko Schöder; Andrew D Seidman
Journal:  Breast Cancer Res Treat       Date:  2021-06-10       Impact factor: 4.872

5.  Repeatability of image features extracted from FET PET in application to post-surgical glioblastoma assessment.

Authors:  Nathaniel Barry; Pejman Rowshanfarzad; Roslyn J Francis; Anna K Nowak; Martin A Ebert
Journal:  Phys Eng Sci Med       Date:  2021-08-26

6.  Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.

Authors:  Francesco Cicone; Luciano Carideo; Claudia Scaringi; Andrea Romano; Marcelo Mamede; Annalisa Papa; Anna Tofani; Giuseppe Lucio Cascini; Alessandro Bozzao; Francesco Scopinaro; Giuseppe Minniti
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

7.  Bevacizumab as a treatment option for radiation necrosis after cranial radiation therapy: a retrospective monocentric analysis.

Authors:  R Bodensohn; I Hadi; D F Fleischmann; S Corradini; N Thon; J Rauch; C Belka; M Niyazi
Journal:  Strahlenther Onkol       Date:  2019-10-04       Impact factor: 3.621

Review 8.  MRI biomarkers in neuro-oncology.

Authors:  Marion Smits
Journal:  Nat Rev Neurol       Date:  2021-06-20       Impact factor: 42.937

Review 9.  Value of PET imaging for radiation therapy.

Authors:  Constantin Lapa; Ursula Nestle; Nathalie L Albert; Christian Baues; Ambros Beer; Andreas Buck; Volker Budach; Rebecca Bütof; Stephanie E Combs; Thorsten Derlin; Matthias Eiber; Wolfgang P Fendler; Christian Furth; Cihan Gani; Eleni Gkika; Anca-L Grosu; Christoph Henkenberens; Harun Ilhan; Steffen Löck; Simone Marnitz-Schulze; Matthias Miederer; Michael Mix; Nils H Nicolay; Maximilian Niyazi; Christoph Pöttgen; Claus M Rödel; Imke Schatka; Sarah M Schwarzenboeck; Andrei S Todica; Wolfgang Weber; Simone Wegen; Thomas Wiegel; Constantinos Zamboglou; Daniel Zips; Klaus Zöphel; Sebastian Zschaeck; Daniela Thorwarth; Esther G C Troost
Journal:  Strahlenther Onkol       Date:  2021-07-14       Impact factor: 3.621

Review 10.  Management of brain metastases according to molecular subtypes.

Authors:  Riccardo Soffietti; Manmeet Ahluwalia; Nancy Lin; Roberta Rudà
Journal:  Nat Rev Neurol       Date:  2020-09-01       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.